
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
AZN | London | GBP | Real-time | |
3LAZ | London | GBP | Real-time | |
3SAZ | London | GBP | Real-time | |
AZNl | BATS Europe | GBP | Delayed | |
AZNs | BATS Europe | SEK | Delayed | |
AZN | NASDAQ | USD | Real-time | |
AZNCF | OTC Markets | USD | Delayed | |
AZNN | BIVA | MXN | Delayed | |
AZNN | Mexico | MXN | Delayed | |
AZN | Stockholm | SEK | Real-time | |
AZNPy | Frankfurt | EUR | Delayed | |
AZN | Frankfurt | EUR | Delayed | |
AZN | TradeGate | EUR | Delayed | |
AZN | Xetra | EUR | Delayed | |
AZN | Buenos Aires | ARS | Delayed |
AstraZeneca PLC reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was USD 286 million compared to USD 152 million a year ago. Revenue was USD 10,879 million compared to USD 11,390 million a year ago. Net income was USD 1,803 million compared to USD 386 million a year ago. Basic earnings per share from continuing operations was USD 1.16 compared to USD 0.25 a year ago. Diluted earnings per share from continuing operations was USD 1.16 compared to USD 0.25 a year ago.
Period Ending: | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 |
---|---|---|---|---|
Total Revenue | 10879 | 11207 | 10982 | 10771 |
Gross Profit | 9106 | 8737 | 8941 | 8942 |
Operating Income | 2687 | 1668 | 2282 | 2021 |
Net Income | 1803 | 901 | 1640 | 360 |
Period Ending: | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 |
---|---|---|---|---|
Total Assets | 96687 | 96483 | 94185 | 96579 |
Total Liabilities | 60876 | 59425 | 59031 | 60628 |
Total Equity | 35811 | 37058 | 35154 | 35951 |
Period Ending: | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | 3133 | 2398 | 2930 | 1248 |
Cash From Investing Activities | -1246 | -249 | -1743 | -800 |
Cash From Financing Activities | -2031 | -358 | -1430 | -1295 |
Net Change in Cash | -155 | 1797 | -294 | -873 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review